Seattle-based Athira Pharma Inc, a developer of regenerative therapies focused on restoring brain function, has closed $85 million in Series B financing. Perceptive Advisors led the round. In connection with the financing, Joseph Edelman, CEO and portfolio manager of Perceptive Advisors, will join Athira Pharma’s board of directors.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: